1 / 16

NIH to Decide the Fate of Revolutionary Gene Editing Technology

National Institutes of Health (NIH)’s Recombinant DNA Advisory Committee (RAC) will review the decision of using the CRISPR/Cas9 technology for the first-in-human use for gene editing.

jesika01
Télécharger la présentation

NIH to Decide the Fate of Revolutionary Gene Editing Technology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NIH to Decide the Fate of Revolutionary Gene Editing Technology

  2. National Institutes of Health (NIH)’s Recombinant DNA Advisory Committee (RAC) will review the decision of using the CRISPR/Cas9 technology for the first-in-human use for gene editing.

  3. The Federal Advisory Committee will review the proposal for test of CRISPR /Cas9 technology on humans on 21st and 22nd June, 2016.

  4. The committee is set up to calculate the potential risk factor of this technology, as the modified T cells can skip the regular checks and bypass that prevent immune system from attacking one’s own tissue.

  5. CRISPR (Clustered regularly interspaced short palindromic repeats) technology is a popular gene editing tool. It is based on a bacterial CRISPR-associated protein-9 nuclease (Cas9) from Streptococcus pyogenes.

  6. It was first observed in bacterial community. The video below explains the CRISPR /Cas9 technology in detail (Video credit: McGovern Institute for Brain Research at MIT).

  7. Future plans of many researchers in renowned Universities as well as high profile biotech companies depend upon the approval of the review.

  8. One of such proposals will be of University of Pennsylvania, where researchers will start their studies of this genome editing technology on humans specifically targeting two genes in the T cells which they aim to edit by using CRISPR.

  9. The T cells will be modified and enabled by the CRISPR technology to encounter the myeloma, melanoma and sarcomas tumor cells. University of Pennsylvania was also a contributor to a pioneer reformed blood cancer treatment where the patient’s blood cells were genetically altered and refused in blood stream to identify and eliminate the cancer cells.

  10. Usually pharmaceutical companies are reluctant to use such novel technologies without trying and testing but CRISPR/Cas9 is an exception to it. As many upstart companies as well as high profile biotech companies are interested in this reliable, efficient and cheap technique.

  11. In short, CRISPR is a powerful gene editing therapy used to cut and paste genes swiftly, precisely and rapidly. Cambridge based therapeutic company “Editas Medicine” are planning to use this technology for a certain rare eye disease and will start their trial somewhere around in 2017.

  12. Several other companies also intend to capitalize on this technique if the green signal is given. Crispr Therapeutics, Caribou Biosciences (and spinoff Intellia Therapeutics) are gearing up to invest in this emerging technology. 

  13. A lot is at stake for the researchers as well as the investors on the decision of the panel. The future of medicine and various treatments lies in the upcoming review. But the technique does come with its own pros and cons.

  14. For More Update, Visit Us http://medgenera.com/

More Related